CryoPort, Inc. CYRX

The latest analyst work on Cryoport points to a higher blended fair value estimate, with price targets moving from US$17.06 to US$19.33, about a 13% uplift in the modeled target level. That shift lines up with more constructive Street commentary, as several bullish analysts highlight Cryoport’s Cell and Gene Therapy logistics and bioservices as key supports for the higher target range. As you read on, you will see how to track these shifting assumptions and what they might mean for your own...

Conestoga Capital Advisors, an asset management company, released its second-quarter 2026 investor letter. A copy of the letter can be downloaded here. The letter reports a positive market shift towards Small Caps, with the Russell 2000 Index achieving its best first half since 1991 and the Russell 2000 Growth Index up 25.7% in Q2, fueled by AI […]

Moby summary of Cryoport, Inc.'s Q2 2026 earnings call

CryoPort Inc (CYRX) achieves positive adjusted EBITDA and reaffirms full-year guidance amid strong biostorage growth and expanding commercial therapy support.

Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a leading global provider of integrated temperature-controlled supply chain solutions for the life sciences, today announced financial results for its second quarter (Q2) and first half (H1) of 2026.

Cryoport is back in focus after the modeled fair value in one framework moved from US$15.61 to US$17.06, signaling a higher price target being used in recent analysis. That shift lines up with Street research that has taken a more constructive tone on the stock, with higher targets in the mid to high teens and above US$20 tied to what analysts view as healthier trends across MVE, BioLogistics, and BioStorage. Read on to see how these updated targets fit into the evolving Cryoport narrative...

Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a leading global provider of integrated temperature-controlled supply chain solutions for the life sciences, today announced that the Company will report financial results for the second quarter ended June 30, 2026 on Thursday, August 6, 2026 after U.S. markets close.

Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a leading global provider of integrated temperature-controlled supply chain solutions for the life sciences, today announced that Cryoport Systems' IntegriCell® cryopreservation services have been selected by Verismo Therapeutics, a clinical-stage CAR T cell therapy company pioneering a novel multi-chain KIR-CAR platform technology for the treatment of solid tumors (SynKIR™-110) and B cell associated disorders and malignancies (SynKIR™

Cryoport’s analyst assessed fair value per share has been updated to US$15.61 from US$13.61, signaling a shift in how research teams are framing the stock’s intrinsic worth. Behind this change, recent reports highlight on the ground work around bioservices operations, with analysts debating how differentiated offerings, demand patterns and cost structure might influence execution and risk around current targets. Read on to see what is driving this evolving narrative and how you can track it...

Moby summary of Cryoport, Inc.'s Q1 2026 earnings call

CryoPort (NASDAQ:CYRX) reported first-quarter fiscal 2026 results that management said reflected continued momentum across its integrated services and products platform, highlighted by double-digit revenue growth in both reporting segments and improved profitability metrics. On the call, CEO Jerrel

CryoPort (CYRX) delivered earnings and revenue surprises of -15.00% and +6.41%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?